Inventor
KRAUSS ACHIM H
US17 patents
⚠️ This page may combine multiple inventors who share the name “KRAUSS ACHIM H”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALLERGAN INC
11 patentsUS5652236AJul 29, 1997
Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
ALLERGAN INC65 citations95
US7070768B2Jul 4, 2006
Method for imparting artificial tan to human skin
ALLERGAN INC40 citations92
US6956057B2Oct 18, 2005
EP4 agonists as agents for lowering intraocular pressure
ALLERGAN INC16 citations92
US5602143AFeb 11, 1997
Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
ALLERGAN INC19 citations92
US7217725B2May 15, 2007
Prostaglandin D2 antagonist
ALLERGAN INC11 citations84
US7045634B2May 16, 2006
Prostamide receptor antagonists
ALLERGAN INC12 citations84
US5741812AApr 21, 1998
Thromboxane ligands without blood clotting side effects
ALLERGAN INC9 citations74
US5516791AMay 14, 1996
7-[carboxyakyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1]octane and derivatives thereof
ALLERGAN INC8 citations74
US5416106AMay 16, 1995
7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof
ALLERGAN INC8 citations74
US5650431AJul 22, 1997
Thromboxane ligands without blood clotting side effects
ALLERGAN INC4 citations63
US7273883B2Sep 25, 2007
Prostaglandin EP4 antagonist
ALLERGAN INC4 citations62
ALLERGAN SALES INC
2 patentsCS PHARMACEUTICALS LTD
2 patentsUS12350277B2Jul 8, 2025
Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
CS PHARMACEUTICALS LTD0 citations48
US11759472B2Sep 19, 2023
Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
CS PHARMACEUTICALS LTD0 citations37
AXEROVISION INC
2 patentsUS10751334B2Aug 25, 2020
Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
AXEROVISION INC0 citations46
US10413535B2Sep 17, 2019
Pharmaceutical compositions comprising an integrin ALPHA4 antagonist for use in treating ocular inflammatory conditions
AXEROVISION INC0 citations46